This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Le Poole, I. C. Articles by Nickoloff, B. J. Search for Related Content PubMed PubMed Citation Articles by Le Poole, I. C. Articles by Nickoloff, B. J.

(American Journal of Pathology. 2002;160:521-528.)
© 2002 American Society for Investigative Pathology

Regular Articles

Interferon- Reduces Melanosomal Antigen Expression and Recognition of Melanoma Cells by Cytotoxic T Cells

I. Caroline Le Poole^*, Adam I. Riker^*, M. Eugenia Quevedo^*, Lawrence S. Stennett^*, Ena Wang, Francesco M. Marincola, W. Martin Kast, June K. Robinson^* and Brian J. Nickoloff^*

From the Department of Pathology,^*
Cardinal BernardinCancer Center, Skin Oncology Research Program, and the CancerImmunology Program,
Loyola University MedicalCenter, Maywood, Illinois; and the SurgeryBranch,
National Institutes of Health,Bethesda Maryland

In malignant melanoma, tumor-infiltrating lymphocytes are frequently reactive with melanosomal antigens. Achieving complete remissions by peptide therapy is frequently hampered by metastases evading immune recognition. The tumor microenvironment seems to favor reduced expression of target antigens by melanoma cells. Among candidate factors, interferon- (IFN-) (10² to 10³ U/ml) suppressed expression of antigens MART-1, TRP-1, and gp100 by M14 melanoma cells as shown by immunohistology and fluorescence-activated cell sorting analysis, reducing MART-1 expression by >65%. Northern blot analysis revealed that reduced expression was regulated at the transcriptional level, demonstrating a 79% reduction in MART-1 transcript abundance after 32 hours of IFN- treatment. To evaluate consequences of IFN- exposure for immune recognition, MART-1-responsive T cells were reacted with pretreated HLA-matched melanoma cells. Cytotoxicity was reduced up to 78% by IFN- pretreatment, and was restored by addition of MART-1 peptide AAGIGILTV for 2 hours. Examination of melanoma lesions by quantitative reverse transcriptase-polymerase chain reaction revealed up to 188-fold more abundant IFN- transcripts when compared to control skin. Laser capture microdissection and immunohistology localized most IFN--producing T cells to the tumor stroma. Reduced MART-1 expression was frequently observed in adjacent tumor cells. Consequently, IFN- may enhance inflammatory responses yet hamper effective recognition of melanoma cells.

This article has been cited by other articles:

				I. S. Dunn, T. J. Haggerty, M. Kono, P. J. Durda, D. Butera, D. B. Macdonald, E. M. Benson, L. B. Rose, and J. T. Kurnick Enhancement of Human Melanoma Antigen Expression by IFN-beta J. Immunol., August 15, 2007; 179(4): 2134 - 2142. [Abstract] [Full Text] [PDF]

				D. Liu, S. J. O'Day, D. Yang, P. Boasberg, R. Milford, T. Kristedja, S. Groshen, and J. Weber Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study Clin. Cancer Res., February 1, 2005; 11(3): 1237 - 1246. [Abstract] [Full Text] [PDF]

				M. J. Dobrzanski, J. B. Reome, J. A. Hollenbaugh, and R. W. Dutton Tc1 and Tc2 Effector Cell Therapy Elicit Long-Term Tumor Immunity by Contrasting Mechanisms That Result in Complementary Endogenous Type 1 Antitumor Responses J. Immunol., February 1, 2004; 172(3): 1380 - 1390. [Abstract] [Full Text] [PDF]

				M. G. Carrabba, C. Castelli, M. J. Maeurer, P. Squarcina, A. Cova, L. Pilla, N. Renkvist, G. Parmiani, and L. Rivoltini Suboptimal Activation of CD8+ T Cells by Melanoma-derived Altered Peptide Ligands: Role of Melan-A/MART-1 Optimized Analogues Cancer Res., April 1, 2003; 63(7): 1560 - 1567. [Abstract] [Full Text] [PDF]

				P. J. Durda, I. S. Dunn, L. B. Rose, D. Butera, E. M. Benson, F. Pandolfi, and J. T. Kurnick Induction of "Antigen Silencing" in Melanomas by Oncostatin M: Down-Modulation of Melanocyte Antigen Expression Mol. Cancer Res., April 1, 2003; 1(6): 411 - 419. [Abstract] [Full Text] [PDF]